A detailed history of Syntax Research, Inc. transactions in Eli Lilly & CO stock. As of the latest transaction made, Syntax Research, Inc. holds 323 shares of LLY stock, worth $241,022. This represents 0.23% of its overall portfolio holdings.

Number of Shares
323
Previous 323 -0.0%
Holding current value
$241,022
Previous $251 Million 16.38%
% of portfolio
0.23%
Previous 0.19%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 06, 2024

BUY
$592.2 - $792.28 $59,220 - $79,228
100 Added 44.84%
323 $251 Million
Q3 2023

Nov 14, 2023

BUY
$434.7 - $599.3 $96,938 - $133,643
223 New
223 $120 Million

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $709B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Syntax Research, Inc. Portfolio

Follow Syntax Research, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Syntax Research, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Syntax Research, Inc. with notifications on news.